Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

05:16
11/30/16
11/30
05:16
11/30/16
05:16

Arrowhead downgraded to Neutral from Overweight at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff downgraded Arrowhead to Neutral and lowered its price target to $2 from $10 following the surprise announcement of its discontinuation of three clinical programs: ARC-520, ARC-521, and ARC-AAT.

  • 30

    Nov

ARWR Arrowhead
$4.39

-0.07 (-1.57%)

08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.